Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma

NCT01176552 is registered in ClinicalTrials.gov with Kidney Cancer Research Bureau as lead sponsor.

NCT NCT01176552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01176552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma
Lead sponsor
Kidney Cancer Research Bureau
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2010
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma